|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
210,690,000 |
Market
Cap: |
480.37(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,271,597 |
52
Week Range: |
$1.94 - $5.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 11.2 |
Insider 6 Months : 11.2 |
Insider 3/6 Months : 22.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
208,225 |
208,225 |
228,225 |
3,561,555 |
Total Buy Value |
$535,647 |
$535,647 |
$594,719 |
$10,594,709 |
Total People Bought |
3 |
3 |
3 |
13 |
Total Buy Transactions |
3 |
3 |
4 |
14 |
Total Shares Sold |
0 |
0 |
0 |
187,843 |
Total Sell Value |
$0 |
$0 |
$0 |
$885,322 |
Total People Sold |
0 |
0 |
0 |
3 |
Total Sell Transactions |
0 |
0 |
0 |
3 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hawkins Richard J |
|
|
2025-06-20 |
4 |
B |
$2.04 |
$98,572 |
D/D |
48,225 |
115,466 |
0.01 |
7% |
|
Mccracken Joseph S |
|
|
2025-05-29 |
4 |
B |
$2.08 |
$20,825 |
D/D |
10,000 |
260,837 |
0.01 |
-1% |
|
Ramsay David A |
|
|
2025-03-31 |
4 |
B |
$2.78 |
$416,250 |
D/D |
150,000 |
2,513,642 |
0.01 |
-20% |
|
Mccabe Kathleen R. |
Chief Legal Officer |
|
2025-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
558,582 |
|
-20% |
|
Lutz Robert Matthew |
Chief Operating Officer |
|
2025-02-13 |
4 |
D |
$2.83 |
$108,284 |
D/D |
(38,263) |
361,737 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-12-13 |
4 |
D |
$3.21 |
$58,624 |
D/D |
(18,263) |
434,672 |
|
- |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2024-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
340,050 |
|
- |
|
Ramsay David A |
|
|
2024-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
2,363,642 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
452,935 |
|
- |
|
Mccracken Joseph S |
|
|
2024-11-19 |
4 |
B |
$2.95 |
$59,072 |
D/D |
20,000 |
210,837 |
0.01 |
2% |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2024-11-10 |
4 |
D |
$3.97 |
$198,302 |
D/D |
(49,950) |
260,050 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-10-21 |
4 |
D |
$3.57 |
$1,360 |
D/D |
(381) |
352,935 |
|
- |
|
Parker Braden C. |
Chief Commercial Officer |
|
2024-09-25 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
85,000 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-07-21 |
4 |
D |
$4.47 |
$1,703 |
D/D |
(381) |
353,316 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-04-21 |
4 |
D |
$4.81 |
$1,833 |
D/D |
(381) |
353,697 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-03-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
354,078 |
|
-7% |
|
Elam Nevan C |
Director |
|
2023-12-28 |
4 |
S |
$4.71 |
$442,291 |
D/D |
(93,843) |
22,500 |
|
-5% |
|
Elam Nevan C |
Director |
|
2023-12-28 |
4 |
OE |
$0.82 |
$69,722 |
D/D |
53,758 |
116,343 |
|
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-28 |
4 |
S |
$4.71 |
$47,131 |
D/D |
(10,000) |
342,355 |
|
-5% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,000 |
1,283,674 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-28 |
4 |
S |
$4.71 |
$395,900 |
D/D |
(84,000) |
1,302,674 |
|
-5% |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
352,355 |
|
- |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
310,000 |
|
- |
|
Sun Ricky |
|
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
450,000 |
1,386,674 |
|
- |
|
191 Records found
|
|
Page 1 of 8 |
|
|